Trial
NCT01649791
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
UnknownTERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI); Celgene Corporation
Condition
B-cell Chronic Lymphocytic Leukemia
Intervention
lenalidomide
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-30